Clinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks

Psychotherapy and Psychosomatics

Volumn 86, Issue 3, 2017, Pages 134-140

  Fava, Giovanni A ^a,b   Tomba, Elena ^a   Bech, Per ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

Behavioral toxicity; Clinical pharmacopsychology; Clinical psychology; Clinimetrics; Iatrogenic comorbidity; Psychotherapy; Rating scales

Indexed keywords

PSYCHOTROPIC AGENT;

BEHAVIOR DISORDER; CLINICAL PSYCHOLOGY; DRUG EFFECT; HUMAN; ILLNESS BEHAVIOR; PATIENT ATTITUDE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; REVIEW; TREATMENT RESPONSE; MENTAL DISEASE; QUALITY OF LIFE; TRENDS;

HUMANS; MENTAL DISORDERS; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; QUALITY OF LIFE;

EID: 85018692497     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000458458     Document Type: Review

References (80)

1. Kraepelin E: Uber die Beeinflussung einfacher psychischer Vorgange durch einige Arzneimittel. Jena, Fischer Verlag, 1892.
2. Bech P: Clinical Psychometrics. Oxford, Wiley-Blackwell, 2012.
3. Pichot P: Introduction; in Pichot P (ed): Psychological Measurements in Psychopharmacology. Basel, Karger, 1974, pp 1-7.
4. Derogatis LR, Lipman RS, Rickels K, Uhlenmuth EH, Covi L: The Hopkins Symptom Checklist (HSCL): a measure of primary symptom dimensions; in Pichot P (ed): Psychological Measurements in Psychopharmacology. Basel, Karger, 1974, pp 79-110.
5. Hamilton M: General problems of psychiatric rating scales (especially for depression); in Pichot P (ed): Psychological Measurements in Psychopharmacology. Basel, Karger, 1974, pp 125-138.
6. Overall JE: The Brief Psychiatric Rating Scale in psychopharmacology research; in Pichot P (ed): Psychological Measurements in Psychopharmacology. Basel, Karger, 1974, pp 67-78.
7. Feinstein AR: On exorcising the ghost of Gauss and the curse of Kelvin. Clin Pharmacol Ther 1971; 12: 1003-1016.
8. Feinstein AR, Wells CK: A new clinical taxonomy for rating angina pectoris. Am Heart J 1977; 93: 172-182.
9. Feinstein AR: The Jones criteria and the challenge of clinimetrics. Circulation 1982; 66: 1-5.
10. Feinstein AR: Clinimetrics. New Haven, Yale University Press, 1987.
11. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
12. Hamilton M: Some notes on rating scales. Statistician 1968; 18: 11-17.
13. Tomba E, Bech P: Clinimetrics and clinical psychometrics: macro- and micro-analysis. Psychother Psychosom 2012; 81: 333-343.
14. Fava GA, Tomba E, Sonino N: Clinimetrics: the science of clinical measurements. Int J Clin Pract 2012; 66: 11-15.
15. Bech P: Clinimetric dilemmas in outcome scales for mental disorders. Psychother Psychosom 2016; 85: 323-326.
16. Piolanti A, Offidani E, Guidi J, Gostoli S, Fava GA, Sonino N: Use of the Psychosocial Index: a sensitive tool in research and practice. Psychother Psychosom 2016; 85: 337-345.
17. Fava GA, Ruini C, Rafanelli C: Psychometric theory is an obstacle to the progress of clinical research. Psychother Psychosom 2004; 73: 145-148.
18. Bech P: Modern psychometrics in clinimetrics: impact on clinical trials of antidepressants. Psychother Psychosom 2004; 73: 134-138.
19. Kellner R: Improvement criteria in drug trials with neurotic patients. Part 2. Psychol Med 1972; 2: 73-80.
20. Kellner R: The measurement of depression and anxiety; in den Boer JA, Sitsen JMA (eds.): Handbook of Depression and Anxiety. New York, Dekker, 1994, pp 133-158.
21. Rasch G: Probabilistic Models for Some Intelligence and Attaintment Tests. Copenhagen, Danish Institute for Educational Research, 1960 (expanded edition: Chicago, Chicago University Press, 1980).
22. Mokken RJ: Theory and Practice of Scale Analysis. Berlin, Mouton, 1971.
23. Fava GA, Staccini L, Delle Chiaie R, Belaise C, Tomba E: Farmacopsicologia clinica. Riv Psichiatr 2014; 49: 251-254.
24. Guidi J, Fava GA: Emerging trends in clinical psychology. Riv Psichiatr 2014; 49: 227.
25. Pedrelli P, Blais MA, Alpert JEW, Shelton RC, Walker RS, Fava, M: Reliability and validity of the Symptoms of Depression Questionnaire (SDQ). CNS Spectr 2014; 19: 535-546.
26. Demyttenaere K, De Fruyt J: Getting what you ask for: on the selectivity of depression rating scales. Psychother Psychosom 2003; 72: 61-70.
27. Faries D, Herrera J, Rayamajhi J, De Brota D, Demitrack M, Potter WZ: The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000; 34: 3-10.
28. Timmerby N, Andersen JH, Sondergaar S, Ostergaard SD, Bech P : A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6). Psychother Psychosom 2017;86: 141-149.
29. Gibbons RD, Clark DC, Kupfer DJ: Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 1993; 27: 259-273.
30. Carroll BJ, Fielding JM, Blashki TG: Depression rating scales. Arch Gen Psychiatry 1973; 28: 361-366.
31. Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP : A comparison of depression rating scales. Br J Psychiatry 1982; 141: 45-49.
32. Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115-127.
33. Bech P: Applied psychometrics in clinical psychiatry. Acta Psychiatr Scand 2009; 120: 400-409.
34. Richardson WS, Doster LM: Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability. J Clin Epidemiol 2014; 67: 244-246.
35. Fava GA, Guidi J, Rafanelli C, Sonino N: The clinical inadequacy of evidence-based medicine and the need for a conceptual framework based on clinical judgment. Psychother Psychosom 2015; 84: 1-3.
36. Di Mascio A, Shader RI: Behavioral toxicity of psychotropic drugs. Conn Med 1968; 32: 617-620.
37. Guidi J, Fava GA, Bech P, Paykel E: The Clinical Interview for Depression. Psychother Psychosom 2011; 80: 10-27.
38. Rothschild AJ, Raskin J, Wamg CN, Marangell LB, Fava M: The relationship between change in apathy and changes in cognition and functional outcomes in currently nondepressed SSRI-treated patients with major depressive disorder. Compr Psychiatry 2014; 55: 1-10.
39. Fava GA, Rafanelli C, Tomba E: The clinical process in psychiatry: a clinimetric approach. J Clin Psychiatry 2012; 73: 173-184.
40. Porcelli P, Guidi J: The clinical utility of the Diagnostic Criteria for Psychosomatic Research. Psychother Psychosom 2015; 84: 265-272.
41. Fava GA, Bech P: The concept of euthymia. Psychother Psychosom 2016; 85: 1-5.
42. Hasler G: Well-being: an important concept for psychotherapy and psychiatric neuroscience. Psychother Psychosom 2016; 255-261.
43. Bech P, Carrozzino D, Austin SF, Moller SB, Vassend O: Measuring euthymia within the Neuroticism Scale of the NEO Personality Inventory. J Affect Disord 2016; 15: 193-199.
44. Tossani E: The concept of mental pain. Psychother Psychosom 2013; 82: 67-73.
45. Blasco-Fontecilla H, Baca-Garcia E, Courtet P, Garcia Nieto R, de Leon J: Horror vacui emptiness might distinguish between major suicide repeaters and non-major suicide repeaters. Psychother Psychosom 2015; 84: 117-119.
46. de Leon J, Baca-Garcia E, Blasco-Fontecilla H: From the serotonin model of suicide to a mental pain model of suicide. Psychother Psychosom 2015; 84: 323-329.
47. Verrocchio MC, Carrozzino D, Marchetti D, Andreasson K, Fulcheri M, Bech P: Mental pain and suicide. Front Psychiatry 2016; 7: 108.
48. Bech P: Social functioning: should it become an endpoint in trials with antidepressants. CNS Drugs 2005; 19: 13-24.
49. Tyrer P, Tyrer H, Guo B: The general neurotic syndrome: a re-evaluation. Psychother Psychosom 2016; 85: 193-197.
50. Bech P, Rickels K: The items predicting nonremission after 6 months of treatment of patients with generalized anxiety disorder covered the Eysenck neuroticism components of anxiety, interpersonal sensitivity and depression. Psychother Psychosom 2016; 85: 229-230.
51. Bech P: Measurement of psychological distress and well-being. Psychother Psychosom 1990; 54: 77-89.
52. Rodriguez-Urrutia A, Eiroa-Orosa FJ, Accarino A, Malagelada C, Azpiroz F: Incongruence between clinicians' assessments and selfreport functioning is related to psychopathology among patients diagnosed with gastrointestinal disorders. Psychother Psychosom 2016; 85: 244-245.
53. Topp CW, Østergaard SD, Søndergaard S, Bech P: The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom 2015; 84: 167-176.
54. Bottomley A, Jones D, Claassens L: Patientreported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicine Agency. Eur J Cancer 2009; 45: 347-353.
55. Clancy C, Collins FS: Patient-Center Outcomes Research Institute: the intersection of science and health care. Sci Transl Med 2010; 3: 37.
56. Fava GA: The concept of recovery in affective disorders. Psychother Psychosom 1996; 65: 2-13.
57. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100.
58. Balon R, Segraves RT: Survey of treatment practices for sexual dysfunction(s) associated with antidepressants. J Sex Marital Ther 2008; 34: 353-365.
59. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs. Psychother Psychosom 2016; 85: 270-288.
60. Karch FE, Lasagna L: Adverse drug reactions. A critical review. JAMA 1975; 234: 1236-1241.
61. Fava GA, Cosci F, Tomba E: Iatrogenic comorbidity in mental health. Psychother Psychosom 2015; 84(suppl 1):22.
62. Fava GA, Cosci F, Offidani E, Guidi J: Behavioral toxicity revisited: iatrogenic comorbidity in psychiatric evaluation and treatment. J Clin Psychopharmacol 2016; 36: 550-553
63. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72-81.
64. Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63-71.
65. Shader RI (ed): Psychiatric Complications of Medical Drugs. New York, Raven Press, 1972.
66. Whitlock FA: Adverse psychiatric reactions to modern medication. Aust NZ J Psychiatry 1981; 15: 87-103.
67. Tisdale JE, Miller DA (eds): Drug-Induced Diseases, ed 2. Bethesda, American Society of Health-System Pharmacists, 2010.
68. Rickels K: Non-specific factors in drug therapy. Springfield, Charles C Thomas, 1968.
69. Zilcha-Mano S, Roose SP, Barber JP, Rutherford BR: Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels? Psychother Psychosom 2015; 84: 177-182.
70. Schedlowski M, Enck P, Rief W, Bingel U: Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev 2015; 67: 697-730.
71. Uhlenhuth EH, Lipman RS, Covi L: Combined pharmacotherapy and psychotherapy. J Nerv Ment Dis 1969; 148: 52-64.
72. Fava GA, Tomba E: New modalities of assessment and treatment planning in depression. CNS Drugs 2010; 24: 453-465.
73. Forand NR, de Rubeis RJ, Amsterdam JD: Combining medication and psychotherapy in the treatment of major mental disorders; in Lambert MJ (ed): Bergin and Garfield's Handbook of Psychotherapy and Behavior Change, ed 6. Hoboken, Wiley, 2013, pp 735-774.
74. Guidi J, Tomba E, Fava GA: The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry 2016; 173: 128-137.
75. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott P, Kirby M, McNamee G, Sengun S, Warkwick K: Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiatry 1993; 162: 776-787.
76. Barlow DH, Gorman JM, Shear MK, Woods SW: Cognitive behavioral therapy, imipramine and their combination for panic disorder. JAMA 2000; 283: 2529-2536.
77. Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbur HP, Wold JE: Exposure therapy and sertraline in social phobia. Br J Psychiatry 2003; 182: 312-318.
78. Nordahl HM, Vogel PA, Morken G, Stiles TC, Sandvik P, Wells A: Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with or without avoidant personality disorder. Psychother Psychosom 2016; 85: 346-356.
79. Fava GA: Conflict of interest in psychopharmacology: can Dr. Jekyll still control Mr. Hyde? Psychother Psychosom 2004; 73: 1-4.
80. Fava GA: The hidden costs of financial conflicts of interest in medicine. Psychother Psychosom 2016; 85: 65-70.